Last updated: August 27, 2026
NEULASTA, Amgen’s pegfilgrastim product, has moved from a multibillion-dollar oncology franchise to a mature biologic under sustained biosimilar pressure. U.S. biosimilar approvals began in 2018, eroding price and volume across the long-acting granulocyte colony-stimulating factor, or G-CSF, market. Amgen has protected part of the franchise through the Neulasta Onpro on-body delivery system, contracting, supply reliability, and physician familiarity.
The commercial outlook is defensive rather than expansionary. Revenue is likely to continue declining as additional biosimilars gain formulary access, although Onpro, provider workflow benefits, and hospital purchasing arrangements support residual share.
What is NEULASTA and how does it compete in oncology supportive care?
NEULASTA is pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor. It stimulates neutrophil production and is used to reduce the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy.
The product is administered once per chemotherapy cycle, typically approximately 24 hours after chemotherapy. Its principal commercial advantage over short-acting filgrastim is reduced injection frequency.
NEULASTA is sold in two principal U.S. delivery formats:
| Product |
Delivery format |
Commercial role |
| Neulasta prefilled syringe |
Manual subcutaneous injection |
Lower-device-cost option |
| Neulasta Onpro |
On-body injector applied after chemotherapy and delivering pegfilgrastim the following day |
Premium convenience and workflow product |
The Onpro system reduces the need for a patient to return to the clinic for a next-day injection. That feature has supported use in community oncology, where treatment capacity, nurse time, transportation, and appointment scheduling affect product selection.
How has the NEULASTA market changed?
The market changed materially after the first U.S. pegfilgrastim biosimilar approvals in 2018. Prior to biosimilar entry, NEULASTA had strong pricing power and limited direct competition. Biosimilar entrants created a lower-price alternative while preserving the same broad therapeutic role.
The main U.S. competitors include:
| Product |
Active ingredient |
Sponsor |
FDA approval |
| Fulphila |
Pegfilgrastim-jmdb |
Biocon Biologics, formerly Mylan/Viatris |
2018 |
| Udenyca |
Pegfilgrastim-cbqv |
Coherus BioSciences |
2018 |
| Ziextenzo |
Pegfilgrastim-bmez |
Sandoz |
2018 |
| Nyvepria |
Pegfilgrastim-apgf |
Pfizer |
2020 |
| Fylnetra |
Pegfilgrastim-pbbk |
Kashiv Biosciences/Amneal |
2022 |
| Stimufend |
Pegfilgrastim-fpgk |
Fresenius Kabi |
2022 |
Udenyca became one of the most visible commercial challengers. Coherus also developed Udenyca OnBody, directly targeting the operational value of Neulasta Onpro rather than competing only on syringe pricing.
Competition has operated through four channels:
- Lower acquisition prices for health systems and oncology practices.
- Formulary substitution and preferred-product contracting.
- Expansion of distributor and group-purchasing access.
- Alternative on-body delivery systems that reduce NEULASTA’s device advantage.
What is the financial trajectory of NEULASTA?
NEULASTA revenue has declined sharply from its pre-biosimilar peak. Amgen’s reported product sales show a long-term contraction caused by biosimilar competition, lower net prices, and declining share in the U.S. market.
| Year |
Approximate Amgen NEULASTA sales |
Primary driver |
| 2018 |
About $4 billion |
Pre-commercial impact of biosimilars |
| 2019 |
About $3.5 billion |
Initial U.S. biosimilar uptake |
| 2020 |
About $2.7 billion |
Broader biosimilar availability and lower pricing |
| 2021 |
About $2.1 billion |
Formulary conversion and share loss |
| 2022 |
About $1.7 billion |
Continued price and volume erosion |
| 2023 |
About $1.4 billion |
Mature biosimilar competition |
| 2024 |
About $1.2 billion |
Further U.S. erosion and franchise maturity |
Values are rounded from Amgen annual-report product-sales disclosures and should be read as directional rather than as a substitute for the company’s reported figures. [1-6]
The decline represents a loss of more than two-thirds from the franchise’s late-2010s revenue base. NEULASTA remains commercially relevant because the underlying clinical use is recurring and tied to chemotherapy cycles, but it no longer has the growth profile of Amgen’s newer products, including Repatha, Evenity, Tezspire and products acquired through Horizon Therapeutics.
Why has NEULASTA revenue declined?
The main financial pressures are:
- Biosimilar price discounts and contracting.
- Payer and provider efforts to reduce supportive-care costs.
- Product switching at the syringe level.
- Growing competition from biosimilar on-body injectors.
- Lower net realized price despite continued unit demand.
- U.S. oncology purchasing consolidation.
The revenue decline is therefore broader than a patent-expiration event. It reflects loss of market exclusivity followed by sustained commercial substitution.
When did NEULASTA lose regulatory exclusivity?
NEULASTA received FDA approval in 2002. The 12-year reference-product exclusivity period created by the Biologics Price Competition and Innovation Act expired in 2014. The first U.S. pegfilgrastim biosimilars were approved in 2018, after the statutory exclusivity period and related patent negotiations had delayed commercial entry. [7,8]
The relevant timeline is:
| Date |
Event |
| January 2002 |
FDA approves NEULASTA |
| 2014 |
BPCIA reference-product exclusivity period expires |
| June 2018 |
FDA approves Fulphila and Udenyca |
| November 2018 |
FDA approves Ziextenzo |
| 2020 |
FDA approves Nyvepria |
| 2022 |
FDA approves Fylnetra and Stimufend |
| 2023-2024 |
Biosimilar competition becomes a mature market force |
Regulatory exclusivity and patent protection are separate. Expiration of the 12-year biologic exclusivity period did not automatically eliminate Amgen’s patent rights.
What patents protect NEULASTA and Neulasta Onpro?
NEULASTA is not subject to the same public patent-listing system as a small-molecule drug. FDA does not publish a conventional Orange Book patent listing for biologics. Biologic reference products and their biosimilars are tracked primarily through the Purple Book, while patent disputes are handled under the BPCIA framework and ordinary federal patent litigation.
The relevant intellectual-property categories are:
Pegfilgrastim composition and use patents
Early patents covered recombinant G-CSF, pegylation approaches, formulations, and therapeutic use. Many foundational patents have expired or have limited remaining commercial significance because the product launched in 2002.
Formulation and stability patents
Formulation claims can cover excipients, protein concentration, pH, stability, aggregation control, and storage conditions. These patents may affect biosimilar development and litigation, but they typically provide narrower protection than a broad composition patent.
Neulasta Onpro device patents
The Onpro system has created a separate patent layer covering the injector, packaging, control mechanisms, adhesive application, drug containment, delivery timing, and interaction between the device and prefilled product.
This device estate is commercially important because it can delay or complicate direct substitution with an on-body biosimilar. It does not eliminate competition against the prefilled syringe presentation.
Manufacturing and process patents
Manufacturing rights may cover pegylation, purification, protein folding, fill-finish, container closure, and device assembly. These rights can increase development cost and create litigation leverage, although FDA biosimilar approval does not require the applicant to use Amgen’s manufacturing process.
Does NEULASTA have an Orange Book listing or Paragraph IV risk?
No conventional Orange Book listing applies because NEULASTA is a biologic rather than a small-molecule drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act.
Paragraph IV certifications are associated with abbreviated new drug applications, or ANDAs. Pegfilgrastim biosimilars use the 351(k) pathway under the Public Health Service Act. Their applicants do not challenge NEULASTA through a standard ANDA Paragraph IV filing.
Biosimilar applicants instead provide patent information under the BPCIA’s patent-exchange process, often called the patent dance, and may face patent litigation before or around launch. The relevant questions are whether the applicant infringes enforceable patents, whether those patents are valid, and whether settlement agreements control the launch date.
Which companies are challenging NEULASTA?
The principal competitive challengers are companies with FDA-approved pegfilgrastim biosimilars:
- Coherus BioSciences, through Udenyca and Udenyca OnBody.
- Viatris and Biocon Biologics, through Fulphila.
- Sandoz, through Ziextenzo.
- Pfizer, through Nyvepria.
- Amneal and Kashiv Biosciences, through Fylnetra.
- Fresenius Kabi, through Stimufend.
The competitive threat is strongest where payers and providers can substitute a prefilled syringe without materially changing workflow. It is more complex in clinics that value the Onpro delivery model.
What litigation and settlement issues affect NEULASTA?
NEULASTA biosimilar litigation has centered on patent portfolios associated with pegfilgrastim formulations, manufacturing, delivery systems, and related products. Amgen has used patent enforcement and negotiated settlements to manage the timing and conditions of biosimilar launches.
Settlement agreements in biologic markets can include:
- An agreed launch date.
- Licenses to specified patents.
- Restrictions on device configurations.
- Geographic limitations.
- Manufacturing or supply conditions.
- Releases for particular patent claims.
Many settlement terms are confidential or disclosed only in part through court filings and company reports. The commercial effect has been to convert uncertain litigation timing into staggered entry rather than a single immediate market opening.
The key analytical distinction is between syringe competition and Onpro competition. A biosimilar may enter the syringe market while facing additional barriers involving an on-body injector.
How strong is the NEULASTA patent estate?
The core NEULASTA molecule has limited remaining life as a practical exclusivity asset because the product was approved more than two decades ago. The stronger portions of the estate are more likely to involve delivery technology, device integration, manufacturing, and specific formulations.
Overall patent strength is best characterized as:
| Asset category |
Current strategic strength |
| Foundational pegfilgrastim composition |
Low to moderate, based on age and expiration history |
| Method-of-use protection |
Limited for ordinary chemotherapy-induced neutropenia use |
| Formulation patents |
Moderate where claim scope and validity remain intact |
| Onpro device patents |
Moderate to high for competing on-body presentations |
| Manufacturing patents |
Product- and process-specific; relevant to litigation but not necessarily market blocking |
| Brand and clinical familiarity |
Commercially meaningful but not patent protection |
The estate can preserve advantages around a delivery system without preventing price competition from biosimilar syringes.
What is the FDA status of NEULASTA biosimilars?
FDA has approved multiple pegfilgrastim biosimilars under the 351(k) pathway. Approval requires analytical similarity, comparable pharmacokinetics and pharmacodynamics, and a totality-of-the-evidence assessment. The products are not automatically interchangeable solely because they are biosimilars.
Interchangeability depends on a separate FDA designation. Pharmacy-level substitution is also governed by state law, payer policy, and institutional purchasing rules.
For NEULASTA, interchangeability is less important in physician-administered oncology settings than in retail pharmacy markets because hospitals and oncology practices often control product selection through contracts and protocols.
What generic launch risks exist for NEULASTA?
The principal launch risk is not a conventional generic launch. It is a multi-product biosimilar erosion scenario.
Base-case scenario
Multiple biosimilars retain access to payer and provider formularies. NEULASTA Onpro preserves a portion of the installed base, while syringe sales experience continued price and volume pressure.
Accelerated-erosion scenario
A competing on-body product secures preferred status with large oncology networks and national payers. Amgen responds with deeper discounts, reducing net sales faster than unit volume declines.
Stabilization scenario
Amgen maintains a defensible Onpro position through device reliability, nursing workflow, contracting, and patient adherence. Revenue continues to fall but at a slower rate as the market reaches a mature equilibrium.
The most important variables are payer preference, provider economics, the spread between syringe and on-body pricing, and the reliability of biosimilar supply.
How does NEULASTA compare with competing G-CSF products?
| Product class |
Example |
Dosing pattern |
Competitive position |
| Long-acting pegfilgrastim |
NEULASTA |
Usually once per chemotherapy cycle |
Convenience and established use |
| Pegfilgrastim biosimilars |
Udenyca, Fulphila, Ziextenzo, Nyvepria |
Usually once per cycle |
Lower price and contracting |
| Short-acting filgrastim |
Neupogen and biosimilars |
Daily or repeated dosing |
Lower acquisition cost, higher administration burden |
| Long-acting non-pegylated G-CSF |
Some regional products |
Product-specific |
Varies by geography and reimbursement |
NEULASTA’s central economic defense is convenience. Its central weakness is that biosimilars replicate the same therapeutic class and can compete on price.
What geographic markets remain attractive?
The United States remains the most consequential market because of historical pricing, oncology volume, and rapid biosimilar penetration. Europe has had biosimilar filgrastim and pegfilgrastim competition for years, with stronger institutional procurement and lower prices.
Emerging markets can offer volume growth but generally produce lower net prices and face local manufacturing, tender, reimbursement, and regulatory barriers. Amgen’s global revenue exposure is therefore increasingly weighted toward maintaining share and price in selected markets rather than expanding the product’s global growth trajectory.
What is the investment outlook for NEULASTA?
NEULASTA is a declining cash-generating asset, not a growth driver. Its financial value lies in residual recurring demand, manufacturing scale, and the ability to monetize the Onpro delivery system.
For Amgen, the key issues are:
- The pace of U.S. biosimilar share loss.
- Net price concessions required to retain accounts.
- Onpro utilization and device-related costs.
- Manufacturing efficiency at lower volumes.
- Litigation and settlement costs.
- Whether declining NEULASTA sales are offset by newer products.
For competitors, the market offers a mature biosimilar opportunity with established clinical demand but limited room for undifferentiated entry. Commercial success depends on contracting, supply reliability, distribution, and an effective delivery format.
Key Takeaways
- NEULASTA is a mature pegfilgrastim franchise with revenue declining from roughly $4 billion in the late 2010s to about $1 billion in 2024.
- FDA’s 12-year biologic exclusivity period expired in 2014.
- The first U.S. pegfilgrastim biosimilars were approved in 2018.
- Paragraph IV ANDA litigation does not apply directly because NEULASTA is a biologic.
- The commercial patent advantage is concentrated in Neulasta Onpro, formulations, device integration, and manufacturing technology.
- Udenyca, Fulphila, Ziextenzo, Nyvepria, Fylnetra, and Stimufend are the principal U.S. biosimilar challengers.
- The main future risk is accelerated substitution into biosimilar syringe and on-body products.
- NEULASTA remains commercially relevant but is unlikely to return to historical growth or pricing levels.
FAQs
Is NEULASTA still commercially important to Amgen?
Yes. NEULASTA remains a recurring oncology-supportive-care product, but its strategic and financial contribution is materially lower than before biosimilar entry.
Is Udenyca interchangeable with NEULASTA?
Udenyca is FDA-approved as a biosimilar to NEULASTA. Biosimilar status alone does not establish automatic pharmacy substitution. Interchangeability and substitution depend on FDA designation and applicable state law.
Does Neulasta Onpro have separate patent protection?
Yes. The on-body injector has separate device, delivery, packaging, and system-related intellectual-property considerations distinct from the pegfilgrastim molecule.
Can a generic manufacturer file an ANDA for NEULASTA?
No. NEULASTA is regulated as a biologic. Competitors generally pursue the 351(k) biosimilar pathway rather than an ANDA.
What is the largest remaining competitive advantage of NEULASTA?
The largest advantage is the established Neulasta Onpro workflow, supported by clinician familiarity, patient convenience, and reduced need for a next-day clinic visit.
References
-
Amgen Inc. (2019). 2018 annual report. https://www.amgen.com/investors/financial-information/annual-reports
-
Amgen Inc. (2020). 2019 annual report. https://www.amgen.com/investors/financial-information/annual-reports
-
Amgen Inc. (2021). 2020 annual report. https://www.amgen.com/investors/financial-information/annual-reports
-
Amgen Inc. (2022). 2021 annual report. https://www.amgen.com/investors/financial-information/annual-reports
-
Amgen Inc. (2024). 2023 annual report. https://www.amgen.com/investors/financial-information/annual-reports
-
Amgen Inc. (2025). 2024 annual report. https://www.amgen.com/investors/financial-information/annual-reports
-
U.S. Food and Drug Administration. (n.d.). Neulasta prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (n.d.). Biosimilar product information. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
-
U.S. Food and Drug Administration. (n.d.). Biologics Price Competition and Innovation Act. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/biologics-price-competition-and-innovation-act-bpci-act
